J Clin Lipidol:ω-3脂肪酸可以降低死亡和心血管疾病风险吗?

2018-06-27 吴星 环球医学

ω-3脂肪酸水平与任何原因的死亡风险和心血管疾病(CVD)发病风险相关到何种程度仍然有争议。2018年5月,发表在《J Clin Lipidol》的一项前瞻性和观察性研究调查了红细胞长链ω-3脂肪酸水平与死亡率和心血管疾病发病风险的相关性。

ω-3脂肪酸水平与任何原因的死亡风险和心血管疾病(CVD)发病风险相关到何种程度仍然有争议。2018年5月,发表在《J Clin Lipidol》的一项前瞻性和观察性研究调查了红细胞长链ω-3脂肪酸水平与死亡率和心血管疾病发病风险的相关性。

目的:旨在Framingham心脏研究中考察其相关性。

设计:前瞻性和观察性队列研究。

机构:Framingham心脏研究后代队列。

测量:暴露标志物为基线时测量的二十碳五烯酸和二十二碳六烯酸(ω-3指数)的红细胞水平。结局指标包括死亡率(总死亡率、CVD相关死亡、癌症和其他)和基线时无CVD的参与者的总CVD事件。中位随访7.3年。Cox比例风险模型调整了18个变量(人口统计学、临床状态、治疗和CVD风险因素)。

结果:2500名参与者中(平均66岁,女性54%),共计发生了350例死亡(CVD相关58例,癌症146例,其他病因明确死亡128例,原因不明18例)。发生了245例CVD事件。多变量调整分析中,较高的ω-3指数与显著性低的总死亡率(P=0.02)、非CVD和非癌症死亡率(P=0.009)、总CVD事件(P=0.008)风险相关。与ω-3指数下五分位数(<4.2%)相比,ω-3指数上五分位数(>6.8%)的任何原因死亡风险降低34%,CVD风险降低39%。与二十碳五烯酸相比较,这些相关性在二十二碳六烯酸中普遍更强烈。当在同一模型中比较总胆固醇和ω-3指数时,后者与这些结局显著相关,而前者无关。

局限性:相对短的随访时间和一次性暴露评估。

结论:较高的ω-3指数与CVD和全因死亡风险的降低相关。

原始出处:

Harris WS, Tintle NL, Etherton MR, et.al. Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study. J Clin Lipidol. 2018 May - Jun;12(3):718-727.e6. doi: 10.1016/j.jacl.2018.02.010. Epub 2018 Mar 2.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-09-23 bettycmoon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2019-04-06 tongyongming
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-06-27 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1656388, encodeId=e4701656388cf, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Sun Sep 23 21:29:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779152, encodeId=15771e79152a2, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat Apr 27 13:29:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778776, encodeId=35991e787763c, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Jan 08 02:29:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703512, encodeId=e3341e0351227, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Sat Apr 06 21:29:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329885, encodeId=96b8132988553, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473124, encodeId=22cf14e31240d, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498435, encodeId=a5c41498435bb, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Jun 29 01:29:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327440, encodeId=e53732e440f1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Jun 27 12:57:39 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327410, encodeId=ac0432e41063, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 27 10:36:10 CST 2018, time=2018-06-27, status=1, ipAttribution=)]
    2018-06-27 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

盘点:不容小觑的ω-3脂肪酸

ω-3脂肪酸是机体的必须脂肪酸,可对机体产生多种健康益处。但是人体并不能合成ω-3脂肪酸,需要从食物中获得。ω-3脂肪酸共有11种类型,其中最重要的3种分别是ALA(α-亚麻酸)、EPA(二十碳五烯酸)和DHA(二十二碳六烯酸)。这里梅斯小编整理了近期关于ω-3脂肪酸的重要研究进展与大家一同分享。【1】Meta分析表明ω-3脂肪酸可降低心脏病、高脂血病风险一项由一个随机对照试验(RCT)的荟萃

JAMA Cardiol:Meta分析:高危患者服用ω-3脂肪酸对心血管无益

近期,牛津大学学者在JAMA内科上发表的一项Meta分析表明,每日补充ω-3脂肪酸(FAS)并不能降低高危人群致命或非致命性冠心病或大血管事件的发生率。

J Hypertens:全血中的ω-3脂肪酸浓度与年轻健康成年人的血压呈负相关!

由此可见,较高的Omega-3指数与血压正常的年轻人和健康人SBP和DBP水平降低之间具有显著相关性。富含n-3 FA的饮食可能是高血压一级预防的策略。

Mayo Clin Proc:ω-3脂肪酸可降低心脏病、高脂血病风险(Meta分析)

一项由一个随机对照试验(RCT)的荟萃分析和另一个前瞻性队列研究的荟萃分析组成的研究表明,美国心脏协会(AHA)关于每天摄入至少1克的二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)来降低冠心病(CHD)事件风险的推荐是合理的。研究结果还表明,那些具有高水平的甘油三酯或低密度脂蛋白胆固醇的患者摄入最佳剂量的ω-3脂肪酸后将获益匪浅。该研究成果发表在今年1月的《梅奥诊所学报》(Mayo Clinic

Stroke:ω-3脂肪酸和缺血性卒中之间的相关性分析!

由此可见,循环中高水平DHA与动脉粥样硬化性脑卒中以及DPA与心源性脑卒中的发生呈负相关。这些新的发现表明DHA、DPA和二十碳五烯酸产生有益效应的作用途径不一样。

Am J Clin Nutr:孕期血浆ω-3脂肪酸含量预示了产后是否肥胖?

2017年5月,发表在《Am J Clin Nutr》的一项基于亚洲女性的队列研究,得出了孕妇血浆ω-3脂肪酸与产后体重保留负相关的结论。